462 Studies Now Enrolling
A Phase 3, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants with Refractory Chronic Inflammatory Demyelinating (CIDP) Polyneuropathy
A Study to Test the Effects and Safety of Riliprubart in People with Chronic CIDP for Which the Usual Treatment Does Not Work
| Sponsor: | Sanofi US Services |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAV0943 |
| U.S. Govt. ID: | NCT06290128 |
| Contact: | Jorge E. Cabrera: / jec2273@cumc.columbia.edu |
Additional Study Information:
This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must be 18 years old at the time of signing the informed consent.
Do You Qualify?
| Are you at least 18 years old? | Yes | No |
| Do you have CIPD or possibly meet the CIDP criteria (typical CIDP, motor CIDP, or multifocal CIDP)? | Yes | No |
| Have you had a failed or poor response to either immunoglobulin therapy or corticosteroid therapy? | Yes | No |
| Do you have Hepatitis B, Hepatitis C or HIV? | Yes | No |
| Have you ever taken riliprubart? | Yes | No |